Lustig Garrett 4

What Happened
Garrett Lustig, a director of Organogenesis Holdings, was granted 48,828 restricted stock units (RSUs) on February 18, 2026. The grant is reported at a $0.00 acquisition price (typical for RSU awards); the units represent the contingent right to one share of Class A common stock per RSU and vest in full on February 15, 2027. This is an equity award (compensation/retention), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (filing appears timely).
• Grant: 48,828 RSUs; reported price: $0.00; reported transaction value: $0.
• Shares owned after transaction: not specified in the filing.
• Footnote: RSUs granted under the Organogenesis 2018 Equity Incentive Plan; each RSU converts to one share upon vesting; full vest on 2027-02-15.
• No indication of a 10b5-1 plan, sale, exercise, or tax-withholding event in this filing.

Context
RSU grants are commonly used for executive/director compensation or retention and do not involve immediate cash outlay or sale of shares. Because these units vest in the future, they only convert into actual shares (and potential market exposure) if the vesting conditions are met on 2027-02-15. This type of filing signals a forward-looking compensation award rather than a current market buy or sell.